|Dr. Scott Koenig M.D., Ph.D.||CEO, Pres & Director||1.05M||783k||1952|
|Mr. James Karrels||Sr. VP, CFO & Corp. Sec.||613.84k||139.42k||1967|
|Dr. Ezio Bonvini||Sr. VP of Research & Chief Scientific Officer||658.21k||N/A||1954|
|Mr. Eric Blasius Risser||Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer||609.91k||523.31k||1973|
|Dr. Stephen L. Eck||Sr. VP of Clinical Devel. & Chief Medical Officer||577.62k||N/A||1955|
|Dr. Christopher Shayne James M.D.||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Jeffrey Stuart Peters||VP & Gen. Counsel||N/A||N/A||1971|
|Dr. Thomas M. Spitznagel||Sr. VP of BioPharmaceutical Devel. & Manufacturing||N/A||N/A||1967|
|Ms. Lynn Cilinski||VP, Controller & Treasurer||N/A||N/A||1958|
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 8; Compensation: 7.